Get In Touch

Jolted by the economic slowdown and the looming patent expiry of blockbuster drugs, the global hospital pharmaceuticals market is forecasted to exhibit a moderate CAGR of 3.9% between 2015 and 2023. Nevertheless, the increasing prevalence of chronic ailments worldwide, coupled with increasing healthcare spending is expected to keep the demand for hospital pharmaceuticals high in the near future. As per Transparency Market Research, the market stood at US$197.3 bn in 2014 and is expected to reach US$280.3 bn by the end of 2023. Emerging economies in Asia Pacific and Rest of the World are currently exhibiting highest demand for hospital pharmaceuticals. 

As per reports from the World Health Organization (WHO), annual cases of cancer globally are expected to reach 22 million by 2030. This combined with the rising incidence of parasitic infections will boost demand for anti-parasitic drugs, thus driving the global hospital pharmaceuticals market in the forthcoming years.

Increasing Pharmaceuticals Spending in U.S. Boosts Prospects of Hospital Pharmaceuticals in North America

Regionally, North America held the largest share in the global market in 2014. The recovery of the pharmaceutical industry and the rise in R&D activities between 2013 and 2014 have bolstered opportunities for the hospital pharmaceuticals market in North America. As per TMR analysis, the increasing spending on pharmaceuticals by the U.S. government has considerably aided in the expansion of the hospital pharmaceuticals market in North America. The market in the region is projected to surge at a CAGR of 3.4% between 2015 and 2023.

Europe has emerged as the second-largest market for hospital pharmaceuticals, primarily due to the presence of renowned research organizations in the region. The sound intellectual property protection norms prevalent in Europe have also helped the market to thrive in the region. However, the region lacks proper reimbursement policies and regulatory framework for encouraging the development of novel therapeutics. This could restrain the market’s growth in Europe.

In the meantime, surging opportunities in Latin America and Asia Pacific will compel vendors to shift their focus from developed economies to emerging nations. The large population base in Asia Pacific, coupled with the increasing spending on research and development of novel therapeutics will aid expansion of the hospital pharmaceuticals market in emerging economies.

 

hospital-pharmaceuticals-market

 

Demand from Oncology Segment to Surge in Response to Increasing Incidence of Cancer

The increasing incidence of cancer worldwide has catapulted the oncology segment at the forefront of the global hospital pharmaceuticals market, by therapeutic class. Cancer types such as stomach, breast, liver, and lung cancer have emerged as the leading causes of deaths due to cancer. The market is forecasted to gain momentum from a strong product pipeline as more drugs receive FDA approvals in the future. Since cancer is often associated with a high mortality rate, scientists around the world are engaged in the discovery of better treatment options and more efficient drugs. Demand for oncology drugs is therefore expected to surge in the forthcoming years. TMR has pegged the oncology segment in the global hospital pharmaceuticals market to rise at a CAGR of 6.35% during the forecast period.

Besides this, the increasing incidence of cardiovascular diseases will also fuel demand from the global hospital pharmaceuticals market. The increasing government initiatives, growing diseases awareness, and therapeutic interventions aimed at curbing the incidence of cardiovascular ailments are likely to boost demand for relevant hospital pharmaceuticals.

Demand for anti-hypersensitive drugs is also expected to increase during the forecast period.

Some of the most prominent vendors operating in the global hospital pharmaceuticals market include Novartis, Pfizer, Roche, Sanofi, Merch &Co., AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Gilead Sciences, and others.

Rise in the Number of Hospitals to Foster Growth of the Hospital Pharmaceuticals Market

Huge increase in the number of hospitals around the world, pharmaceutical firms are likely to observe a strong rise in opportunities for growth in the global hospital pharmaceuticals market. With a rise in the number of important pharmaceutical companies penetrating the domain of oncology, which is actually amongst the most profitable therapeutic sectors in the global hospital pharmaceuticals market, the competitive environment is likely to intensify.

The massive rise in occurrence of various chronic diseases like diabetes, cancer, and a multitude of cardiovascular conditions is likely to work in favor of the global hospital pharmaceuticals market in near future. In addition to that, increasing healthcare expenses throughout the developing countries are further likely to drive the demand for hospital pharmaceuticals in near future. The market is anticipated to expand in the face of increasing rate of parasitic infection, which has increased hospital demand for anti-parasitic drugs. The rising number of cancer patients is also another factor propelling the market forward, and it is predicted to continue to be a key driving force in the years to come.

High Prevalence of Diseases like Cancer and Cardiovascular Diseases to Boost Demand

According to World Health Organization (WHO) statistics, cardiovascular diseases account for approximately 31% of all fatalities worldwide each year. As a result, hospital pharmacies dispense a significant volume of medicinal and diagnostic drugs for cardiovascular problems. However, due to a high level of market saturation, the sector of cardiovascular diseases is expected to grow at a slower rate than other indications in the years to come. On the other hand, due to the rising number of cases of cancer detected each year around the world, the oncology sector is anticipated to see a massive increase in valuation. Increased prevalence of such diseases worldwide is likely to pave way for rapid growth of the global hospital pharmaceuticals market in near future.

Pharmaceutical drugs are sold through various channels such as retail, mail orders, clinics and hospitals. This report on the global hospital pharmaceuticals market analyses the current and future prospects of the market specifically pertaining to drugs sold in hospital settings. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a robust combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ million for each segment for the period from 2013 to 2023, considering the macro and micro environmental factors. Growth rates for each segment within the global teleradiology market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

Market revenue in terms of US$ Mn for the period between 2013 and 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all the segments, considering 2014 as the base year. Global hospital pharmaceutical drugs market is segmented according to major therapeutic areas, which include: cardiology, oncology, nephrology and urology, neurology, pain and infection. Market for these major therapeutic areas has been further assessed according to drug classes. Cardiology segment is further divided into anti-hypertensive drugs, dyslipidemia drugs, and others (ACE inhibitors, angiotensin receptor blockers, anticoagulants). Oncology segment is further segmented into immunomodulating agents, alkylating agents, anti-metabolites, hormonal agents, and miscellaneous drugs. Nephrology and urology segment is further divided into diuretic drugs, anti-hypertensive agents, phosphate binders, anti-cholinergic agents and 5-alpha-reductase inhibitors. Neurology segment is divided into anti-anxiety, anti-migraine, anti-depressant and anti-psychotic drugs. Market for pain management drugs has been divided into anti-convulsant drugs, anesthetics, nonsteroidal anti-inflammatory drugs (NSAID), opioids, and non-narcotic analgesic drugs. Similarly anti-infective drugs market has been segmented into anti-bacterial drugs, anti-viral drugs, anti-fungal drugs and anti-parasite drugs. The report also provides a detailed list of potential phase III candidates for each of the therapeutic areas.

The market has been further studied from the point of view of major diseases in these therapeutic areas. Thus the cardiology market has been studied considering coronary heart diseases, stroke, high blood pressure (hypertension), heart failure and other cardiovascular diseases. Oncology drugs market has been studied for lung cancer, breast cancer, colorectal cancer, prostate cancer, and others. Nephrology and urology drugs market is studied for acute kidney failure, chronic kidney diseases, glomerular diseases, diabetes and other diseases. Neurology market has been studied for epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, stroke and other diseases.

Market for pain has been studied for neuropathic pain, fibromyalgia, osteoarthritis, rheumatoid arthritis, cancer pain and others. The infection market is studied for major infectious disease such as tuberculosis, pneumonia, hepatitis A, hepatitis B, Candida infections, fungal meningitis, shigellosis, amoebiasis and other infections. The report also provides insights for various branded and blockbuster drugs under various therapeutic drug class. Moreover, the report also provides the approval date and the patent expiry for major drugs in the event impact analysis section.

Additionally, the report contains market attractiveness analysis by geography and competitive landscape by key players. The market attractiveness analysis explains the intensity of competition in the market in different geographies. The competitive scenario between different market players is evaluated through market share analysis. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Geographically, this market has been segmented into four regions: North America, Europe, Asia-Pacific, Latin America, and Rest of the World (RoW). In addition the regions have been further segmented by major countries from each region, which include the U.S, Canada, Japan, China, U.K., Germany and Brazil. The report also profiles major players in the hospital pharmaceuticals market based on various attributes such as company overview, financial overview, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Novartis, and Pfizer, Inc.

The global hospital pharmaceuticals market has been segmented as follows: 

Global Hospital Pharmaceuticals Market, by Therapeutic Class

  • Cardiology
    • Anti-hypertensives
    • Dyslipidemia drugs
    • Others
  • Oncology
    • Alkylating Agents
    • Anti-metabolites
    • Hormonal Agents
    • Immunomodulating Agents
    • Miscellaneous Drugs
  • Nephrology and Urology
    • Diuretic Agents
    • Anti-hypertensive Agents
    • Phosphate Binders
    • Anticholinergic Drugs
    • 5-Alpha Reductase Inhibitors
  • Neurology
    • Anti-anxiety Agents
    • Anti-migraine Drugs
    • Antidepressant Drugs
    • Anti-psychotic Drugs
  • Pain
    • Anticonvulsant Drugs
    • Anesthetic Drugs
    • Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Opioids
    • Non-narcotics Analgesic Drugs
  • Infection
    • Antibacterial Drugs
    • Antiviral Drugs
    • Antifungal Drugs
    • Antiparasite Drugs

Global Hospital Pharmaceuticals Market, by Indication

  • Cardiology
    • Coronary Heart Diseases
    • Stroke
    • High Blood Pressure
    • Heart Failure
    • Others
  • Oncology
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Others
  • Nephrology and Urology
    • Acute Kidney Failure
    • Chronic Kidney Diseases
    • Glomerular Diseases
    • Diabetes
    • Others
  • Neurology
    • Epilepsy
    • Alzheimer’s Disease
    • Parkinson’s Disease
    • Multiple Sclerosis
    • Others
  • Pain
    • Neuropathic Pain
    • Fibromyalgia
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Cancer Pain
  • Infection
    • Tuberculosis
    • Pneumonia
    • Hepatitis A
    • Hepatitis B
    • Candida Infection
    • Fungal Meningitis
    • Shigellosis
    • Amoebiasis
    • Other

Global Hospital Pharmaceuticals Market, by Geography

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • Rest of APAC
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Rest of the World

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Table of Content

1. Preface
    1.1. Report Description
    1.2. Market Segmentation
    1.3. Research Methodology
    1.4. Assumptions

2. Executive Summary
    2.1. Global Hospital Pharmaceuticals Market Revenue, by Therapeutic Area, 2014 & 2023 (US$ Mn)
    2.2. Global Hospital Pharmaceuticals Market Revenue, by Countries, 2014 (US$ Mn)
    2.3. Global Hospital Pharmaceuticals Market Revenue, by Geography, 2014 & 2023 (US$ Mn)
    2.4. Global Hospital Pharmaceuticals Market, 2014 & 2023: Market Snapshot 

3. Global Hospital Pharmaceuticals Market – Industry Analysis
    3.1. Introduction
    3.2. Market Dynamics
          3.2.1. Drivers
                  3.2.1.1. Driver 1 - Increased emergency department visits drive demand for hospital drugs
                  3.2.1.2. Driver 2 - Rise in spending on medicines
                  3.2.1.3. Driver 3 - High prevalence of diseases across the world
                  3.2.1.4. Driver 4- Trend towards increase in use of telemedicine technology by hospitals
          3.2.2. Restraints
                  3.2.2.1. Restraint 1- Patent Expirations of Blockbuster Drugs
                  3.2.2.2. Restraint 2- Shift toward use of home health care services
          3.2.3. Opportunities
                  3.2.3.1. Opportunity 1- Extensive R&D activities lead to introduction of new drugs in market
                  3.2.3.2. Opportunity 2- Increasing no. of hospitals in developing economies
    3.3. Event Impact Analysis
    3.4. Value Chain Analysis
    3.5. Market Attractiveness Analysis: Global Hospital Pharmaceuticals Market
    3.6. Market Share Analysis: Global Hospital Pharmaceuticals Market, by Key Players, 2013 (Value %)

4. Market Segmentation – By Product Type
    4.1. Introduction
          4.1.1. Global Hospital Pharmaceuticals Market Revenue, by Major Therapeutic Area, (U.S. $ Mn), 2013-2023
    4.2. Cardiology
          4.2.1. Introduction
          4.2.2. Global Cardiology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, (US$ Mn), 2013-2023
          4.2.3. Global Antihypertensive Drugs Market Revenue, (US$ Mn), 2013-2023
          4.2.4. Global Dyslipidemia Drugs Market Revenue, (US$ Mn), 2013-2023
          4.2.5. Global Other Cardiology Drugs Market Revenue, (US$ Mn), 2013-2023
    4.3. Oncology
          4.3.1. Introduction
          4.3.2. Global Oncology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, (US$ Mn), 2013-2023
          4.3.3. Global Immunomodulating Agents Market Revenue, (US$ Mn), 2013-2023
          4.3.4. Global Alkylating Agents Market Revenue, (US$ Mn), 2013-2023
          4.3.5. Global Anti-metabolites Market Revenue, (US$ Mn), 2013-2023
          4.3.6. Global Hormonal Agents Market Revenue, (US$ Mn), 2013-2023
          4.3.7. Global Miscellaneous Oncology Drugs Market Revenue, (US$ Mn), 2013-2023
    4.4. Nephrology and Urology
          4.4.1. Introduction
          4.4.2. Global Nephrology and Urology Hospital Pharmaceuticals Market Revenue, by Therapeutic Classs, (US$ Mn), 2013-2023
          4.4.3. Global Diuretics Market Revenue, (US$ Mn), 2013-2023
          4.4.4. Global Anti-Hypertensives Market Revenue, (US$ Mn), 2013-2023
          4.4.5. Global Phosphate Binders Market Revenue, (US$ Mn), 2013-2023
          4.4.6. Global Anti-Cholinergics Market Revenue, (US$ Mn), 2013-2023
          4.4.7. Global 5-alpha-reductase Inhibitors Market Revenue, (US$ Mn), 2013-2023
    4.5. Neurology
          4.5.1. Introduction
          4.5.2. Global Neurology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, (US$ Mn), 2013-2023
          4.5.3. Global Diuretics Market Revenue, (US$ Mn), 2013-2023
          4.5.4. Global Anti-Anxiety Market Revenue, (US$ Mn), 2013-2023
          4.5.5. Global Anti-Migraine Market Revenue, (US$ Mn), 2013-2023
          4.5.6. Global Anti-Depressant Market Revenue, (US$ Mn), 2013-2023
          4.5.7. Global Anti-Psychotics Market Revenue, (US$ Mn), 2013-2023
    4.6. Pain
          4.6.1. Introduction
          4.6.2. Global Pain Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, (US$ Mn), 2013-2023
          4.6.3. Global Anti-Convulsants Market Revenue, (US$ Mn), 2013-2023
          4.6.4. Global Anesthetics Market Revenue, (US$ Mn), 2013-2023
          4.6.5. Global NSAID's Market Revenue, (US$ Mn), 2013-2023
          4.6.6. Global Opioids Market Revenue, (US$ Mn), 2013-2023
          4.6.7. Global Non-Narcotic Agents Market Revenue, (US$ Mn), 2013-2023
    4.7. Infection
          4.7.1. Introduction
          4.7.2. Global Infection Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, (US$ Mn), 2013-2023
          4.7.3. Global Anti-Bacterial Drugs Market Revenue, (US$ Mn), 2013-2023
          4.7.4. Global Anti-Viral Drugs Market Revenue, (US$ Mn), 2013-2023
          4.7.5. Global Anti-Fungal Drugs Market Revenue, (US$ Mn), 2013-2023
          4.7.6. Global Anti-Parasite Drugs Market Revenue, (US$ Mn), 2013-2023

5. Market Segmentation – By Indication
    5.1. Introduction
          5.1.1. Global Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
    5.2. Cardiology
          5.2.1. Global Cardiology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
          5.2.2. Global Coronary Heart Disease Market Revenue, (US$ Mn), 2013-2023
          5.2.3. Global Stroke Market Revenue, (US$ Mn), 2013-2023
          5.2.4. Global High Blood Pressure Market Revenue, (US$ Mn), 2013-2023
          5.2.5. Global Heart Failure Market Revenue, (US$ Mn), 2013-2023
          5.2.6. Global Other Cardiology Indications Market Revenue, (US$ Mn), 2013-2023
    5.3. Oncology
          5.3.1. Global Oncology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
          5.3.2. Global Lung Cancer Market Revenue, (US$ Mn), 2013-2023
          5.3.3. Global Breast Cancer Market Revenue, (US$ Mn), 2013-2023
          5.3.4. Global Colorectal Cancer Market Revenue, (US$ Mn), 2013-2023
          5.3.5. Global Prostate Cancer Market Revenue, (US$ Mn), 2013-2023
          5.3.6. Global Other Oncology Indications Market Revenue, (US$ Mn), 2013-2023
    5.4. Nephrology and Urology
          5.4.1. Global Nephrology and Urology Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
          5.4.2. Global Acute Kidney Failure Market Revenue, (US$ Mn), 2013-2023
          5.4.3. Global Chronic Kidney Diseases Market Revenue, (US$ Mn), 2013-2023
          5.4.4. Global Glomerular Diseases Market Revenue, (US$ Mn), 2013-2023
          5.4.5. Global Diabetes Market Revenue, (US$ Mn), 2013-2023
          5.4.6. Global Other Nephrology and Urology Indications Market Revenue, (US$ Mn), 2013-2023
    5.5. Neurology
          5.5.1. Global Neurology Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
          5.5.2. Global Epilepsy Market Revenue, (US$ Mn), 2013-2023
          5.5.3. Global Alzheimer's Disease Market Revenue, (US$ Mn), 2013-2023
          5.5.4. Global Parkinson's Disease Market Revenue, (US$ Mn), 2013-2023
          5.5.5. Global Multiple Sclerosis Market Revenue, (US$ Mn), 2013-2023
          5.5.6. Global Stroke Market Revenue, (US$ Mn), 2013-2023
          5.5.7. Global Other Neurology Indications Market Revenue, (US$ Mn), 2013-2023
    5.6. Pain
          5.6.1. Global Pain Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
          5.6.2. Global Neuropathic Pain Market Revenue, (US$ Mn), 2013-2023
          5.6.3. Global Fibromyalgia Market Revenue, (US$ Mn), 2013-2023
          5.6.4. Global Osteoarthritis Market Revenue, (US$ Mn), 2013-2023
          5.6.5. Global Rheumatoid Arthritis Market Revenue, (US$ Mn), 2013-2023
          5.6.6. Global Cancer Pain Market Revenue, (US$ Mn), 2013-2023
          5.6.7. Global Other Pain Indications Market Revenue, (US$ Mn), 2013-2023
    5.7. Infection
          5.7.1. Global Infection Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
          5.7.2. Global Tuberculosis Market Revenue, (US$ Mn), 2013-2023
          5.7.3. Global Pneumonia Market Revenue, (US$ Mn), 2013-2023
          5.7.4. Global Hepatitis A Market Revenue, (US$ Mn), 2013-2023
          5.7.5. Global Hepatitis B Market Revenue, (US$ Mn), 2013-2023
          5.7.6. Global Candida Infection Market Revenue, (US$ Mn), 2013-2023
          5.7.7. Global Fungal Meningitis Market Revenue, (US$ Mn), 2013-2023
          5.7.8. Global Shigellosis Market Revenue, (US$ Mn), 2013-2023
          5.7.9. Global Amoebiasis Market Revenue, (US$ Mn), 2013-2023
          5.7.10. Global Other Infection Indications Market Revenue, (US$ Mn), 2013-2023

6. Market Segmentation – By Geography
    6.1. Global Hospital Pharmaceuticals Market Revenue, by Geography, (US$ Mn), 2013-2023
    6.2. North America Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.2.1. U.S. Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.2.2. Canada Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
    6.3. Europe Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.3.1. U.K. Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.3.2. Germany Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.3.3. Rest of Europe Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
    6.4. Asia Pacific Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.4.1. China Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.4.2. Japan Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.4.3. Rest of Asia Pacific Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
    6.5. Latin America Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.5.1. Brazil Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.5.2. Mexico Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
          6.5.3. Rest of Latin America Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
    6.6. Rest of the World Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023

7. Company Profiles
    7.1. AztraZeneca plc
    7.2. Bayer AG
    7.3. Bristol-Myers Squibb Company
    7.4. Eli Lilly and Company
    7.5. GlaxoSmithKline plc
    7.6. Johnson and Johnson
    7.7. Merck and Co., Inc.
    7.8. Novartis AG
    7.9. Pfizer, Inc.
    7.10. Sanofi-Aventis

List of Tables

TABLE 1 Market Snapshot: Global Hospital Pharmaceuticals Market
TABLE 2 Major Patent Expirations in Forecast Period
TABLE 3 Event Impact Analysis: Hospital Pharmaceutical Market
TABLE 4 Global Hospital Pharmaceuticals Market Revenue, by Major Therapeutic Areas, 2013-2023 (US$ Million)
TABLE 5 Cardiology Pipeline Overview
TABLE 6 Oncology Pipeline Overview
TABLE 7 Nephrology and Urology Pipeline Overview
TABLE 8 Neurology Pipeline Overview
TABLE 9 Pain Pipeline Overview
TABLE 10 Infection Pipeline Overview
TABLE 11 Global Hospital Pharmaceuticals Market Revenue, by Indication, (US$ Mn), 2013-2023
TABLE 12 Global Hospital Pharmaceuticals Market Revenue, by Geography, (US$ Mn), 2013-2023

List of Figures

FIG. 1 Global Teleradiology Market Share, by Geography, 2014 (Value %)
FIG. 2 Hospital Pharmaceuticals Market Segmentation
FIG. 3 Global Hospital Pharmaceuticals Market, by Therapeutic Area, 2014 & 2023 (US$ Million)
FIG. 4 Global Hospital Pharmaceuticals Market Revenue, by Countries, 2014 (US$ Mn)
FIG. 5 Comparative Analysis: Global Hospital Pharmaceuticals Market, by Geography, 2014 & 2023 (Value %)
FIG. 6 Global Hospital Pharmaceutical Market, Value Chain Analysis
FIG. 7 Market Attractiveness Analysis: Global Hospital Pharmaceutical Market, by Geography, 2014
FIG. 8 Market Share Analysis: Global Hospital Pharmaceutical Market, by Key Players, 2014 (Value %)
FIG. 9 Global Hospital Pharmaceuticals Market, Cardiology Segmentation 
FIG. 10 Global Cardiology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 11 Global Hospital Pharmaceuticals Market, Oncology Segmentation 
FIG. 12 Global Oncology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 13 Global Hospital Pharmaceuticals Market, Nephrology and Urology segmentation
FIG. 14 Global Nephrology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 15 Global Hospital Pharmaceuticals Market, Neurology Segmentation
FIG. 16 Global Neurology Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 17 Global Hospital Pharmaceuticals Market, Pain Segmentation 
FIG. 18 Global Pain Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 19 Global Hospital Pharmaceuticals Market, Infection Segmentation
FIG. 20 Global Infection Hospital Pharmaceuticals Market Revenue, by Therapeutic Class, 2013-2023 (US$ Mn)
FIG. 21 Global Hospital Pharmaceuticals Market, segmentation by Indication
FIG. 22 Global Cardiology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 23 Global Oncology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 24 Global Nephrology and Urology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 25 Global Neurology Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 26 Global Pain Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 27 Global Infection Hospital Pharmaceuticals Market Revenue, by Indications, (US$ Mn), 2013-2023
FIG. 28 Comparative Analysis: Global Hospital Pharmaceuticals Market Revenue, by Geography (Value %), 2014 & 2023
FIG. 29 North America Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
FIG. 30 Europe Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
FIG. 31 Asia Pacific Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
FIG. 32 Latin America Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
FIG. 33 Rest of the World Hospital Pharmaceuticals Market Revenue, (US$ Mn), 2013-2023
FIG. 34 AstraZeneca plc: Annual Revenue, 2012 – 2014 (US$ Million)
FIG. 35 Bayer AG Annual Revenue: 2012 – 2014 (US$ Million)
FIG. 36 Bristol-Myers Squibb Company: Annual Revenue, 2012 – 2014 (US$ Million)
FIG. 37 Eli Lilly and Company: Annual Revenue, 2012 – 2014 (US$ Million)
FIG. 38 GlaxoSmithKline plc: Annual Revenue, 2012 – 2014 (US$ Million)
FIG. 39 Johnson & Johnson: Annual Revenue, 2012– 2014 (US$ Million)
FIG. 40 Merck & Co., Inc.: Annual Revenue, 2012 – 2014 (US$ Million)
FIG. 41 Novartis AG Annual Revenue: 2012 – 2014 (US$ Million)
FIG. 42 Pfizer, Inc.: Annual Revenue 2012 – 2014 (US$ Million)
FIG. 43 Sanofi: Annual Revenue, 2012 – 2014 (US$ Million)

 

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Hospital Pharmaceuticals Market